It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession sparked by the ongoing global trade war. Most bigwigs came out with important ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no ...

Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...

"China's biotechnology sector thrives on a dual engine — Beijing's constellation of famous medical universities training ...

Pharmaceutical stocks fell across Asian markets after U.S. President Trump said he plans to impose a "major" tariff on all pharmaceutical imports.

Vietnam will impose a temporary anti-dumping levy of up to 37.13% on some galvanised steel products originating from China, ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...

Amid the global wave of digital transformation in the healthcare industry, China's market is evolving from a "primary sales hub" to a "primary innovation hub." Recently, Hong Chow, Executive Vice ...